Compare KMPR & AMLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KMPR | AMLX |
|---|---|---|
| Founded | 1990 | 2014 |
| Country | United States | United States |
| Employees | 7400 | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 2.0B |
| IPO Year | N/A | 2021 |
| Metric | KMPR | AMLX |
|---|---|---|
| Price | $28.51 | $22.82 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $47.67 | $21.56 |
| AVG Volume (30 Days) | 813.2K | ★ 1.9M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.85% | N/A |
| EPS Growth | N/A | ★ 65.46 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $380,786,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.35 | N/A |
| P/E Ratio | $14.38 | ★ N/A |
| Revenue Growth | N/A | ★ 1612.94 |
| 52 Week Low | $22.69 | $7.61 |
| 52 Week High | $54.90 | $24.36 |
| Indicator | KMPR | AMLX |
|---|---|---|
| Relative Strength Index (RSI) | 56.87 | 76.43 |
| Support Level | $29.76 | $12.46 |
| Resistance Level | $30.97 | N/A |
| Average True Range (ATR) | 1.16 | 1.43 |
| MACD | 0.01 | 0.39 |
| Stochastic Oscillator | 67.92 | 97.69 |
Kemper Corp is an insurance holding company that offers complementary insurance products through its subsidiaries, including personal and commercial automobile insurance to consumers in targeted markets and industries. Kemper also offers life and other insurance solutions based on the needs of its clients. The company offers its insurance products through a vast network of agents and brokers, mainly under the Kemper Auto and Kemper Life brands. It has two operating segments: Specialty Property & Casualty Insurance and Life Insurance. The majority of the company's revenue is generated from the Specialty Property & Casualty Insurance segment, whose principal products are specialty personal automobile and commercial automobile insurance. Geographically, it operates only in the United States.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.